MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy
Top Cited Papers
Open Access
- 1 November 2005
- journal article
- Published by American Society of Hematology in Blood
- Vol. 106 (9), 3150-3159
- https://doi.org/10.1182/blood-2005-02-0553
Abstract
Although TP53 mutations are rare in acute myeloid leukemia (AML), inactivation of wild-type p53 protein frequently occurs through overexpression of its negative regulator MDM2 (murine double minute 2). Recently, small-molecule antagonists of MDM2, Nutlins, have been developed that inhibit the p53-MDM2 interaction and activate p53 signaling. Here, we study the effects of p53 activation by Nutlin-3 in AML cells. Treatment with MDM2 inhibitor triggered several molecular events consistent with induction of apoptosis: loss of mitochondrial membrane potential, caspase activation, phosphatidylserine externalization, and DNA fragmentation. There was a positive correlation in primary AML samples with wild-type p53 between baseline MDM2 protein levels and apoptosis induced by MDM2 inhibition. No induction of apoptosis was observed in AML samples harboring mutant p53. Colony formation of AML progenitors was inhibited in a dose-dependent fashion, whereas normal CD34+ progenitor cells were less affected. Mechanistic studies suggested that Nutlin-induced apoptosis was mediated by both transcriptional activation of proapoptotic Bcl-2 family proteins, and transcription-independent mitochondrial permeabilization resulting from mitochondrial p53 translocation. MDM2 inhibition synergistically enhanced cytotoxicity of cytosine arabinoside and doxorubicin in AML blasts but not in normal hematopoietic progenitor cells. p53 activation by targeting the p53-MDM2 interaction might offer a novel therapeutic strategy for AML that retain wild-type p53.Keywords
This publication has 63 references indexed in Scilit:
- Lack of Correlation between p53-Dependent Transcriptional Activity and the Ability to Induce Apoptosis among 179 Mutant p53sCancer Research, 2005
- Activation of p53 by MDM2 Antagonists Can Protect Proliferating Cells from Mitotic InhibitorsCancer Research, 2005
- Susceptibility to cytosine arabinoside (Ara-C)-induced cytotoxicity in human leukemia cell linesToxicology Letters, 2004
- Direct Activation of Bax by p53 Mediates Mitochondrial Membrane Permeabilization and ApoptosisScience, 2004
- Phosphorylation Site Interdependence of Human p53 Post-translational Modifications in Response to StressPublished by Elsevier BV ,2003
- Apoptosis Genes and Resistance to Cancer Therapy: What Does the Experimental and Clinical Data Tell Us?Cancer Biology & Therapy, 2003
- mdm2 Is Critical for Inhibition of p53 during Lymphopoiesis and the Response to Ionizing IrradiationMolecular and Cellular Biology, 2003
- Novel cancer therapy by reactivation of the p53 apoptosis pathwayAnnals of Medicine, 2003
- Live or let die: the cell's response to p53Nature Reviews Cancer, 2002
- Prostaglandin A2 and Δ12‐prostaglandin J2 induce apoptosis in L1210 cellsFEBS Letters, 1993